Compare KE Holdings Inc (BEKE) vs Medpace Holdings Inc (MEDP) Price & Performance

BEKE trades at $17.42, down 1.3% today but showing technical bullish signals with strong analyst support. The company reported mixed quarterly results with a Q1 2026 earnings beat but missed Q4 2025 expectations. Revenue declined from $94.6B in 2025 to $90.1B projected for 2026, though net profit margin improved to 3.76%. Technical indicators show bullish momentum with ADX signals supporting upward trend potential.

Outlook remains positive with 92% analyst buy ratings, though investors face risks from China's property market volatility and recent revenue contraction. The stock's valuation at P/E 38.5 appears elevated relative to growth, requiring sustained earnings improvement to justify current multiples. Cash flow trends show improvement with operating cash flow turning positive in 2026 projections.

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.